Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $30.00.

A number of equities research analysts have issued reports on KYTX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. Wall Street Zen cut shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. JPMorgan Chase & Co. reduced their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Kyverna Therapeutics in a research report on Wednesday, June 3rd.

Kyverna Therapeutics Trading Up 2.4%

NASDAQ:KYTX opened at $8.63 on Thursday. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $524.86 million, a PE ratio of -2.63 and a beta of 1.95. The firm’s 50 day moving average is $8.84 and its 200 day moving average is $8.60. Kyverna Therapeutics has a 12 month low of $2.52 and a 12 month high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. Sell-side analysts expect that Kyverna Therapeutics will post -2.78 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio purchased a new position in Kyverna Therapeutics in the third quarter worth $28,000. Grey Ledge Advisors LLC bought a new stake in Kyverna Therapeutics in the first quarter worth $86,000. EntryPoint Capital LLC bought a new stake in Kyverna Therapeutics in the fourth quarter worth $94,000. Phoenix Wealth Advisors lifted its stake in Kyverna Therapeutics by 17.1% in the fourth quarter. Phoenix Wealth Advisors now owns 12,300 shares of the company’s stock worth $116,000 after purchasing an additional 1,800 shares during the last quarter. Finally, Ameriprise Financial Inc. bought a new stake in Kyverna Therapeutics in the third quarter worth $77,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.